{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-015882","form_type":"8-K","ticker":null,"cik":"0001673772","company_name":"RAPT Therapeutics, Inc.","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.849466+00:00","generated_at":"2026-05-16T09:33:48.301958+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"RAPT Therapeutics to be acquired by GSK for $58/share in all-cash tender offer","bullets":["GSK subsidiary will commence tender offer at $58.00 per share in cash within 10 business days.","Company termination fee set at $78.4M; reverse termination fee payable by GSK at $100.8M.","Support agreements cover ~0.25% of outstanding shares; Board recommends tender.","Transaction expected to close by July 19, 2026, subject to HSR clearance and majority tender condition."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-015882","json":"https://secwatch.observer/filing/0001193125-26-015882.json","markdown":"https://secwatch.observer/filing/0001193125-26-015882.md","text":"https://secwatch.observer/filing/0001193125-26-015882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1673772/000119312526015882/0001193125-26-015882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1673772/000119312526015882/d12800d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:33:48.301958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8780b494d3832d22c20342e83bd6532b04d78cb9","claim":"RAPT Therapeutics, Inc. entered into Merger Agreement with GlaxoSmithKline LLC, Redrose Acquisition Co., GSK plc (effective 2026-01-19).","evidence_excerpt":"RAPT Therapeutics, Inc., a Delaware corporation (the “ Company ” or “ RAPT Therapeutics ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, GlaxoSmithKline LLC, a Delaware limited liability company (“ Parent ”), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”) and, solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales (“ Ultimate Parent ” or “ GSK ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1673772/000119312526015882/0001193125-26-015882-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"GlaxoSmithKline LLC, Redrose Acquisition Co., GSK plc"},{"label":"Effective","value":"2026-01-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}